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Sllmmary 
We have investigated the ability of resting B cells, acting as antigen-presenting cells, to induce 
tolerance to soluble protein antigens in mice, using an antigen targeted specifically to B cells. 
We  inject  mice  intravenously with  ultracentrifuged  Fab  fragments  of rabbit  anti-mouse 
immunoglobulin D (IgD) (Fab anti-/~). Treatment with Fab anti-~ results in profound tolerance 
to challenge with 100 #g Fab nonimmune  rabbit Ig (Fab NRG), precipitated in alum, as measured 
by antibody production. Tolerance to rabbit Pub is antigen specific, since the treated mice make 
normal antibody responses to a control antigen, chicken Ig. Tolerance is dependent on antigen 
presentation by B ceils, since intravenous injection of soluble Fab NRG, which is not targeted 
to B cells, results in a much lower frequency and degree of tolerance,  especially at lower doses. 
T  cell help in this system is affected, since T  cells from Fab anti-~treated mice fail to provide 
help for an adoptive primary antibody response to Fab NRG when transferred  together with 
normal B cells into severe combined immunodeficient (SCID) mice. The antigen-specific B cell 
compartment is also affected during tolerance induction, since B cells from treated animals make 
less antibody than normal B cells when transferred into SCID mice with normal T cells. Although 
the mechanism of nonresponsiveness in the helper T cell compartment remains to be determined, 
we think it is likely that the precursors ofhdper T cells are inactivated or deleted by encountering 
antigen presented by small, resting B cells, which lack accessory signals necessary to induce helper 
T cell proliferation and differentiation to effector function. Our experiments suggest a role for 
small B cells as antigen-specific, tolerizing antigen-presenting cells in acquired tolerance to foreign 
protein antigens and in self-tolerance  to soluble stir-proteins. 
E 
ffective antigen presentation results from the interaction 
of a T cell  self-MHC plus a  receptor with  spedfic for- 
eign peptide. During T/B cell collaboration in the antibody 
response,  additional signals are required for this interaction 
to be productive from both the T  and B cell perspectives. 
These additional signals include adhesion and/or signaling 
by cell surface molecules and cytokines, some of which re- 
main to be identified. A two-signal hypothesis was first put 
forth by Bretscher and Cohn (1) for B cells and by Lafferty 
et al. (2) for T  cells. A more spedfic model has been pro- 
posed by Schwartz and colleagues  (3, 4) who have shown 
that fixed APCs or signals that engage the TCR alone de- 
liver an abortive signal to type 1 Th cell lines, which results 
in anergy. This abortive signal produces a rise in intracellular 
Ca  2  + and an increase in the expression of IL-2 receptors, but 
no secretion of Ib2, and the cells remain unresponsive to com- 
plete activation signals for weeks (4). 
B cells get help from T cells in the antibody response by 
acting as antigen-specific APCs, and they can drive T  cell 
proliferation in vitro and in vivo (5, 6, and reviewed in refer- 
ence 7). On the other hand, resting B calls have been found 
to be ineffective (8-11) or inferior (12-14) APCs for primary 
responses to alloantigens and foreign antigens. Overall,  the 
evidence indicates that unmanipulated, small, resting B cells 
are poor APCs for primary T cell responses, although they 
can provide the necessary interactions to get hdp from an 
already  activated  T  cell. 
In this paper, we propose that presentation of antigen by 
a small, resting B cell to a small resting T cell is tolerogenic 
and results in loss oft call activity. This modal is supported 
by evidence from Kyan et al. (15) that in vivo injection of 
small (accessory cell-depleted) spleen cells from allogeneic 
donors into normal mice produced hyporesponsiveness in 
MLK which lasted at least  13 d posttransfer. More recent 
evidence of B cell involvement in tolerance induction, to the 
bin12 mutation in the I-A  b MHC class II molecule, comes 
from Hori et al. (16), who have shown that injection of (bin12 
x  B6)F1 accessory cell-depleted spleen calls into B6 mice 
results in prolonged survival of bm12 skin grafts and abol- 
ishes the MLR against bin12 cells. The predominant MHC 
class II-bearing cell in this population is a small B cell. 
Starting in the early sixties, a series of investigators showed 
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ultracentrifuged  to remove aggregates) produced tolerance 
to a challenge with a more immunogenic form of the same 
antigen (usually in CFA or IFA). These antigens include BSA 
(17),  human gamma globulin (HGG) 1 (18), bovine gamma 
globulin  (19),  and flagellin (20).  Injection of low doses of 
these proteins, in either a single or multiple dose(s) over sev- 
eral weeks, produced tolerance in normal animals that lasted 
up to several weeks. This type of low zone, soluble protein 
antigen tolerance has been shown to involve the inactivation 
of Th cell function (21, 22). The APC that mediates toler- 
ance induction has not been defined. Using low doses of deag- 
gregated antigen, the most likely APCs are the relatively rare 
antigen-specific B cells, which have antigen-specific Ig mole- 
cules on their surface.  These B cells could concentrate and 
process the antigen, but would not be activated by binding 
antigen  since deaggregated  antigen  would not crosslink B 
cell membrane Ig. As outlined above, the interaction of an 
antigen-specific resting T cell with an antigen-specific resting 
B cell may be ineffective due to a lack of costimulatory signal 
or signals,  which are already present or unnecessary in previ- 
ously activated cells. 
Our laboratory has previously shown that  small B cells 
can process and present Fab fragments of rabbit anti-mouse 
Ig very efficiently to our rabbit Ig-specific Th cell lines (23). 
Fab anti-~ alone does not activate B cells in vitro; they show 
no increases in MHC class II expression, size, or DNA syn- 
thesis  (23).  Since we know that  small,  resting  B cells can 
process this antigen while remaining in a resting state (24), 
we felt that this would be a good system for looking at an- 
tigen presentation by small B cells to naive T cells. The Fab 
anti-~  is  ultracentrifuged  and  injected  intravenously  into 
normal mice that  are challenged intraperitoneally  7 d later 
with Fab NRG precipitated in alum.  Confirming  our pre- 
liminary experiments reported earlier (25), these treated mice 
are profoundly tolerant to rabbit Fab compared with untreated 
control mice.  Comparable  treatment  of mice with an Fab 
rabbit Ig molecule not targeted to B ceils,  or with a cross- 
linking F(ab')2 anti-8, is much less effective. Since the treated 
animals are tolerant in the Th cell compartment,  the most 
probable interpretation  of these results is that Fab anti-8 is 
presented on B cells and induces tolerance in T  calls specific 
for rabbit Fab. 
Materials and Methods 
Mice.  BALB/c  ￿  DBA/2 mice (CD2)Ft and BALB/c mice 
were from the National Cancer Institute (Frederick, MD). Female, 
age-matched mice were used in each experiment and the mice were 
8-20 wk old at the start of each experiment. Mice with SCID (CB.17 
SCID mice) (26) and CB.17 mice were bred at the University of 
Massachusetts Medical Center animal facility and were from stock 
kindly provided by Donald Moiler (Medical Biology Institute,  La 
Jolla, CA). The mice were injected and bled from their lateral tail 
veins. 
1  Abbreviations used in this paper: anti-ars, rabbit anti-azophenyl arsonate; 
HGG, human gamma globulin; NR.G, nonimmune rabbit Ig. 
Antigens and Antibodies.  Rabbit anti-mouse IgD was prepared 
in rabbits as previously described (27). The antibody was purified 
from rabbit  sera by affinity chromatography  on IgD columns, 
removing anti-IgG and anti-IgM crossreactivity first. Immunopre- 
cipitation of 6 chains but not/~ chains from l~I-labeled B cells was 
done to check specificity (23). Fab fragments were prepared by in- 
cubating intact  antibody with papain coupled to agarose (Sigma 
Chemical Co., St. Louis, MO) and then separated from Fc frag- 
ments by passage over protein A-Sepharose columns. F(ab')2 frag- 
ments were prepared by pepsin digestion.  Rabbit anti-azophenyl 
arsonate (anti-ars) antibody was prepared in rabbits and purified 
by affinity chromatography.  Nonimmune rabbit Ig (NRG), pre- 
pared from Cohn fractions II and III, was purchased from Sigma 
Chemical Co. Absorbed Fab NRG was prepared by incubating Fab 
NRG (at 1 mg/ml) with whole mouse spleen cells (one spleen/1 
ml of Fab NRG) for I h at 4~  Chicken Ig was purchased from 
Calbiochem-Behring Corp. (LaJolla, CA). BSA was purchased from 
United  States Biochemical  Corp.  (Cleveland, OH).  Rabbit 
anti-mouse  H+L  chain  or isotype-specific horseradish  peroxi- 
dase-coupled  antibodies were purchased from Southern Biotech- 
nology Associates (Birmingham,  AL). CFA was purchased from 
Gibco Laboratories (Grand Island, NY). Killed Bordetella pertussis 
was purchased from the Biological Laboratories at the State Labo- 
ratory Institute  (Jamaica Plain, MA). Endotoxin levels in antigens 
were measured by Pyrotell Limulus amebocyte lysate  assay  (Associates 
of Cape Cod, Woods Hole, MA). All antigens used had <15 ng 
endotoxin/mouse at the maximum injected dose. 
Tolerance Induction.  Molecules used as tolerogens  were cen- 
trifuged  at 160,000 g in an airfuge (Beckman Instruments,  Inc., 
Palo Alto, CA) for 60 rain, and the top 60% of the solution was 
used. Tolerogens were injected in a vohme of 0.2 ml in PBS intra- 
venously into the lateral tail vein of the mice. After 7 d, the animals 
were challenged intraperitoneally with 100/~g ofFab NILG precipi- 
tated in alum. Most animals also received 20/~g chicken Ig precipi- 
tated in alum at a separate site intraperitoneally. The animals were 
bled from the tail veins at weekly intervals, and the serum was 
tested for anti-rabbit Fab antibodies. 
ELISA.  Antibody titers were measured by a sandwich ELISA 
in which serial dilutions of mouse sera starting  at 1:40 were in- 
cubated with antigen (F[ab']2 NRG or chicken Ig) bound to flex- 
ible polyvinylchloride plates (Becton Dickinson Labware, Oxnard, 
CA) and blocked with 1% BSA in PBS. The plates were washed 
with PBS  +  0.05% Tween 20 (polyoxyethelene-sorbitan mono- 
laurate) (Sigma Chemical Co.) and incubated with rabbit anti-mouse 
IgG H+L chain or antiisotype  antibody coupled to horseradish 
peroxidase. The substrate and color developer were 3,3',5,5'-tetra- 
methyl-benzidine  (ICN Biologicals, Lisle, IL) with H202 added. 
The reactions were stopped by the addition of 2 M H2SO4. Plates 
were read at 405 vs. 530 nm on an ELISA platereader (Dynatech 
Laboratories, Inc., Alexandria, "CA), and antibody concentrations 
determined by comparing OD with a mouse anti-rabbit  Fab stan- 
dard that had been purified by affinity chromatography.  Analysis 
of antibody titers was made by logistic analysis (Immunosoft|  Dy- 
natech Laboratories, Inc.), and those dilutions in the most accurate 
range  of  the  plate  reader  were  averaged to  provide  micro- 
gram/milliliter  equivalents. 
Adoptive Transf~  BALB/c  mice were injected intravenously  with 
100/~g Fab anti-#. On day 5, spleen and lymph node cells were 
harvested, The spleen cells were depleted of T cells as previously 
described (23) by treatment  with an  anti-T  cell cocktail  (anti- 
Thy-1, anti-CD4,  and anti-CDS) followed by a mouse anti-rat  K 
antibody and then agarose-absorbed guinea pig complement (tol- 
erant B cells). The lymph node cells were depleted of B cells by 
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Wysocki and Sato (28) (tolerant T cells). These cells, along with 
T and B cells  collected  and separated  from untreated control BALB/c 
mice (normal T and normal B), were transferred  intravenously  into 
SCID mice. 2 d later, the reconstituted SCID mice were challenged 
intraperitoneally with 100/~g Fab NRG + 20/~g chicken Ig, each 
precipitated in alum. All SCID mice were shown to have  <5 #g/ml 
Ig (by ELISA)  before transfer. T cells were <1% slg + and B cells 
were <1% Thy-1  + when stained with biotinylated anti-mouse Ig 
or anti-Thy-1 plus FITC-avidin. 
Results 
Anti-8 Injected  into Mice Induces  Tolerance to Rabbit Glob- 
ulin.  Our  model system involves  injection of 100/~g  of 
ultracentrifuged Fab rabbit anti-/~ intravenously into normal 
CD2F1 mice followed by challenge with Fab NRG precipi- 
tated in alum 7 d later.  These animals become profoundly 
tolerant to rabbit Fab as measured by antibody production 
in an ELISA. Fig.  1 shows the results of one such experi- 
ment. These mice were followed weekly until day 64 post- 
challenge, when three of the six tolerant mice still made <5% 
of the mean control anti-rabbit Fab response. The difference 
between the control and tolerant mice is generally greatest 
at day 21 or 28 postchallenge. At this point the control mice 
approach their peak response and the tolerant mice remain 
unresponsive. In all mice to date, 35 of 50 mice made <1% 
of the mean control anti-rabbit Ig response at day 21 post- 
challenge. Only two of the remaining mice made responses 
>10%  (15  and 20%)  (data not shown). 
Tolerance generated by this method is antigen specific as 
shown by the response to an unrelated antigen given at the 
same time as the rabbit Fab challenge. As shown in Fig. 2, 
these animals all made normal responses  to challenge with 
chicken Ig, also precipitated in alum, given at a different site. 
B  Cells Must Be Targeted  for Tolerance to Occur.  To show 
that the tolerance was due to presentation by B cells, we used 
a rabbit Ig molecule that was not targeted to B ceils. For 
this purpose we used either Fab NRG or Fab rabbit anti-ars. 
Figure 2.  Response  to chicken  Ig is intact. Serum  anti-chicken  Ig anti- 
body  levels  (/~g/ml)  from  the same  mice  shown  in Fig. 1. Mice  were  chal- 
lenged at the same time as challenge  with NRG with 20/~g chicken  Ig 
precipitated in alum at a separate site. Antibody  levels were measured  by 
ELISA at the indicated days postchallenge. 
Each of these antigens was ultracentrifuged and injected in- 
travenously, and as shown in Fig. 3, neither of these mole- 
cules, when injected at this dose (100 #g), were as effective 
as Fab anti-/L In this and most other experiments with injec- 
tion of 100/~g ofFab NRG, a diminished response was found 
(in all experiments,  11 of 23 mice were <10%  of controls 
at day 21 postchallenge while five were >50%  of the con- 
trols) (data not shown). Since injection ofFab NRG intrave- 
nously lowered the subsequent response to challenge with 
Fab NRG precipitated in alum, we decided to compare the 
dose required to induce tolerance by these two protocols. Since 
there is probably some antimouse activity in the commercial 
NRG preparation, we absorbed Fab NRG before injection 
with mouse spleen cells to lessen any rabbit antimouse reac- 
tivity. Fig. 4 shows the dose response of injection of 50,  5, 
or 0.5/~g/mouse Fab anti-~ or absorbed Fab NRG. At a dose 
Figure 1.  Fab anti-6 treatment  induces  tolerance  to rabbit Fab. Serum 
anti-rabbit Fab antibody  levels (/~g/ml)  from mice  injected  intravenously 
with 100/~g ultracentrifuged  lab rabbit anti-/~  or control  untreated  mice 
challenged with 100 #g Fab NRG precipitated in alum. Antibody  levels 
were measured  by ELISA at the indicated days postchallenge. 
Figure 3.  Form  and specificity  of tolerogen  is important. Mean serum 
anti-rabbit Fab antibody  levels (/~g/ml)  from five  groups of mice treated 
with different  forms  and specifidties  of Fab rabbit Ig. On the left is the 
mean response of the six mice shown  in Fig. 1. Next is the average  re- 
sponse from six mice injected  intravenously  with 100 ~g F(ab')z anti-~; 
six mice  injected  with 100/~g  Fab rabbit anti-ars;  three  mice  injected  with 
100/~g Fab NRG; and three  control  untreated mice. All mice  were chal- 
lenged  as above  and antibody  levels  measured  by F.LISA.  Bars  represent 1 SD. 
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Figure  4.  Dose  response  of Fab  anti-& vs.  Fab  NRG.  Mean  serum 
anti-rabbit  Fab antibody levels (/zg/ml) from mice injected intravenously 
with 50, 5, or 0.5 #g/mouse of Fab anti-~ or Fab NRG absorbed with 
mouse spleen cells, and control uninjected  mice. There were seven mice 
in each group. Challenge and antibody measurements are as in Fig. 1. Bars 
represent  1 SD. 
of 50/zg/mouse, the two treatments were almost equivalent, 
but at lower doses Fab anti-/~ was a dearly superior tolerogen. 
Treatment with 0.5/~g Fab anti-/~ was more effective than 
treatment with 5/zg/mouse of absorbed Fab NRG. By tar- 
geting the rabbit Fab fragment to the majority of B cells, 
we have made a much more eflficient tolerogen.  These data 
support  our  hypothesis  that  small  B  cells  are  tolerance- 
inducing APCs. 
Divalent F(a~/)2 Anti-# Does Not Induce Toleranc~  Since  ac- 
tivated B cells have been shown to initiate some T cell re- 
sponses in vitro (8), activated B cells may no longer be tolero- 
genie  as  APCs.  Finkelman et  al.  (29)  have shown  that 
intravenous injection  of whole goat  anti-mouse ~ induces 
Polydonal B cell activation followed by the appearance of large 
numbers of surface IgG-positive cells and T cell-dependent 
IgG secretion. In addition, Golub and Weigle  (30) showed 
that injection of LPS around the time of the tolerogen (HGG) 
blocked the induction  of tolerance. We tested the effects of 
B cell activation in our system by injecting 100/~g of ultracen- 
trifuged  F(ab')2 fragments  of rabbit anti-/~ into  mice  fol- 
lowed by challenge as above. This divalent antigen can cross- 
link the surface IgD molecules, and, as shown in Fig. 3, the 
F(ab')2 anti-fi did not induce tolerance. We were not able in 
this system to rule out effects caused by aggregation of the 
small amount of serum IgD (31), but the simplest interpre- 
tation of these results is that the B cells must remain in a 
resting  state to induce tolerance. 
Adjuvants.  Although most of our tolerance induction has 
been tested with alum-precipitated challenge, we wanted to 
know if mice were still tolerant after challenge with other 
adjuvants since different adjuvants may stimulate different 
subsets oft ceils (32, 33). We treated animals with Fab anti-~ 
and then  challenged  them with  100/zg  Fab NRG either 
precipitated in alum, or precipitated in alum plus 2  x  10  s 
pertussis (both injected intraperitoneally), or emulsified in 
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Figure 5.  Challenge with ~t  adjuvants. (a) Mean serum anti-rabbit 
Fab antibody response (/~g/ml) from mice treated with Fab anti-~3 as in 
Fig. 1 and then challenged after 7 d with 100/~g Fab NRG either precipi- 
tated  in alum alone,  or with 2  x  10  s R  Fertussis  intraperitoneally,  or 
emulsified in CFA subcutaneously.  All anti-/~ groups contain six mice and 
all control groups contain four mice each. Bars represent 1 SD. (b) Mean 
serum anti-rabbit  Fab antibody response by isotype from mice shown in 
Fig.  5. Sera were tested in ELISA using horseradish peroxidase--coupled 
goat  anti-mouse isotype antibodies. 
CFA and injected at the base of the tail. As shown in Fig. 
5 a, the alum-challenged animals with or without/~ pertussis 
remain tolerant. CFA partially breaks tolerance, since anti-6- 
treated mice challenged with CFA make 18% of the mean 
control  response (1,156 #g/ml)  at day 35  postchallenge. 
Since murine Th cell subsets have been defined in vitro 
that induce switching to different Ig isotypes (34), we were 
interested to see if there was a different spectrum of isotypes 
in the residual antibody response in the tolerant mice versus 
the controls. Individual isotype responses, from the sera shown 
in Fig. 5 a, were measured by ELISA with goat anti-mouse 
isotype-specific antibodies. Antibody concentrations were cal- 
culated using mouse anti-ars antibodies of different isotypes 
as standards. The data are presented in Fig. 5 b as a percentage 
of the whole response, since the anti4~-treated mice make 
little antibody at this time (day 35 postchallenge).  There is 
no major difference in the isotypes of anti-rabbit Fab made 
in the anti-/~-treated mice. Although there are differences in 









F  E 
z 







￿9  PRE-tMMUNE 
[]  DAY  14 
[]  DAY  21 
[]  DAY  28 
[]  DAY  35 
Figure 6.  Adoptive transfe~ Mean anti-rabbit Fab response 0~g/ml) from 
SCID mice reconstituted with T and/or B cells from normal, untreated 
BALB/c mice or BALB/c mice injected with 100 ~g Fab anti-6 as in Fig. 
1.  Each group shown contained  five SCID mice that received 8  x  107 
pooled spleen B cells and 2  x  107 pooled lymph node T cells from either 
tolerant or normal mice. Mice were bled weekly and anti-rabbit Fab levels 
measured by ELISA. Symbols, in the last two groups only, represent the 
anti-rabbit Fab responses of the individual mice. Also included in this ex- 
periment but not shown were three mice that received 2  x  107 normal 
T  cells alone or 8  x  107 normal B cells alone. Neither of these groups 
made an anti-rabbit Fab response. 
the isotypes produced in mice challenged with different ad- 
juvants, the predominant isotype in all groups (whether control 
or anti-8 treated) was IgG1. We also tested the mice shown 
in Figs. I and 3 and found no differences in the Ig isotypes 
produced: >90% of the response at day 35 postchallenge was 
IgG1 in all groups (data  not shown). 
T Cell Help Is Compromised  in Fab Anti-d-treatedMicA  To 
look at T  and B cell function in these anti-8-treated mice, 
T  or B cells from anti-&treated BALB/c mice were trans- 
ferred, before challenge, with normal B or T cells into SCID 
mice. The SCID recipient mice were challenged and bled 
weekly, and the data from this adoptive primary antibody 
response are presented in Fig.  6. SCID mice that received 
tolerant T plus tolerant B cells, as expected, made <1/zg/ml 
of anti-rabbit Fab. Tolerant T plus normal B cells gave slightly 
higher anti-rabbit Fab titers, which were 2% of the control 
response at day 21. Tolerant B plus normal T cells gave low 
anti-rabbit Fab responses  that reached 34%  of control re- 
sponses by day 35. These data indicate that there is a loss 
of rabbit Fab-specific  Th cell activity in the anti-8-treated 
mice. There is also a decrease in the responses generated using 
tolerant B cells with normal T  cells, which indicates  that 
there is also some effect on the antigen-spedfic B cell com- 
partment. 
As a control for reconstitution and the specificity of toler- 
ance, these mice were also challenged with chicken Ig and 
then tested for anti-chicken Ig antibodies at days 7 and 14 
postchallenge. All four groups shown made similar levels of 
anti-chicken Ig (data not shown). SCID mice that received 
normal T cells only or normal B cells only followed by chal- 
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lenge as above did not make anti-rabbit Fab or chicken Ig 
antibodies, indicating that the mice did not have sufficient 
T or B cells of their own to mount an immune response and 
that the level of T  and B cell contamination in the trans- 
ferred cell preparation was not a factor in the responses. 
Discussion 
We have shown here that targeting a monovalent soluble 
protein antigen to B cells in vivo increases the et~ciency of 
induction of tolerance in the Th cell compartment. This re- 
sult  contrasts with early experiments showing that cell- 
assodated antigen is exceptionally immunogenic  (35) and more 
recent experiments showing that T cell determinants on an 
allotypic IgG molecule are at least 100 times more immuno- 
genie in vivo when the IgG molecule is directed against class 
II MHC alleles on APC (36).  In experiments superficially 
resembling ours, Finkelman et al. (29) obtained massive, T 
cell-dependent polyclonal B cell activation and Ig secretion 
instead of tolerance when they injected goat anti-6 antibodies 
into mice. In our experiments, instead of intact anti-~ anti- 
body, we used monovalent, uhracentrifuged Fab fragments. 
We have shown that Fab anti-~ does not activate small B cells 
through their antigen receptors but can be effldently  presented 
to T  cell lines in vitro (23, 24).  Resting B cells have been 
shown to be defective APCs for primary responses to foreign 
antigens (10, 11). We propose that the result of defective an- 
tigen presentation in vivo by resting B cells to unprimed T 
cells is tolerance in the T cell compartment. This hypothesis 
offers an attractive explanation for the phenomenon of low- 
zone acquired tolerance to soluble proteins (17), and suggests 
a role for self-reactive  B cells in maintaining tolerance to soluble 
self-proteins. 
Tolerance to soluble protein antigens is usually described 
as a loss of reactivity to a normally immunogenic protein 
induced by administration of that protein by an alternate route, 
dose, or form of administration. One consequence of these 
methods of administration is that the antigen may be processed 
by an alternate or inappropriate APC. In the case of low doses 
of soluble protein antigens, the tolerizing APC may be the 
small antigen-specific B cell. Although these cells are present 
at low frequency (between one in 104 or 10  s for protein an- 
tigens) (37), they may be the only cells with the ability to 
pick up enough of a low-dose, soluble antigen to affect the 
T cell response. If no other APC can gather enough antigen, 
these few small B cells could present it over time to the antigen- 
specific T cells. Resting B cells may also act as tolerizing APC 
in high-zone tolerance to soluble proteins, because at high 
antigen concentrations, all the B cells can take up protein 
antigens nonspecifically (23), and B cells far outnumber other 
constitutively class II-positive cells. 
Fab anti-8 was much more effective at tolerance induction 
than Fab fragments of rabbit IgG (Fab NRG), particularly 
at lower concentrations of tolerogen (Fig. 4). We think this 
is because antigen-specific naive T cells are much more likely 
to encounter antigen presented by a resting B cell in the anti- 
&treated animals: Fab anti-8 can be presented by every IgD- 
positive B cell, while Fab NRG is presented effectively only by rare antigen-specific  B cells. In our experiments, single 
injections of ultracentrifuged Fab NRG produced variable 
effects on the antibody response to subsequent challenge with 
Fab NRG in adjuvant, ranging from no effect (25) to toler- 
ance (Fig. 4). We have not yet identified the source of this 
variability,  which does not correlate with the low levels of 
endotoxin in our tolerogen preparations.  It may be a conse- 
quence of the condition of the mice or of improving tech- 
nique in intravenous injection, since Fab NRG has become 
increasingly tolerogenic over the course of these experiments. 
In classical  low-zone tolerance, repeated injections of tolerogen 
were  required  (17), although  single injections of whole 
nonspecific IgG have been very effective (18, 19). Whole IgG 
may be a more effective tolerogen than Fab fragments be- 
cause of its longer half-life in vivo, 5-6 d vs. ~,4 h (38, 39). 
Tolerance generated in this system is not permanent. Over 
the times tested most mice made an antibody response to 
the alum depot of rabbit Fab. Since the original tolerogen 
is present for such a short time and mice are not challenged 
for an additional 6 d, it is possible that newly emerging im- 
mune cells can reconstitute the anti-rabbit Fab response. Mice 
treated with Fab anti-8 have been challenged as early as 48 h 
after treatment (data not shown), and there is no significant 
difference in the decay of tolerance between mice challenged 
at 2 d posttreatment or 7 d posttreatment. Alternatively,  a 
very small number of peripheral pre-Th cells that escape toler- 
ance induction during the anti-8 treatment may expand over 
the weeks after challenge. 
We looked at T cell function in these anti-8-treated mice 
in two ways. First, in classical carrier-specific help for an an- 
tihapten response, we found diminished help for an anti-DNP 
antibody response when mice were challenged with DNP- 
NKG (data not shown). The second look at T cell function 
was in the adoptive transfer system. Here we reconstituted 
SCID mice with combinations of T and B cells from tolerant 
and control mice and then challenged these mice with Fab 
NKG and looked at the anti-rabbit Fab antibody response. 
These mice had a clear defect in rabbit Fab-specific T  cell 
help, since the mice receiving tolerant T plus normal B cells 
made very reduced amounts of anti-rabbit Fab. The adop- 
tive transfer  into SCID mice showed that the rabbit Fab- 
specific B cells had also been affected by the anti4$ treatment. 
The response of mice receiving tolerant T  plus tolerant B 
cells was even smaller than that of mice receiving tolerant 
T  plus normal B cells, and B cells from tolerant mice plus 
normal T  cells transferred into SCID mice made approxi- 
mately one-third of the response of mice that received normal 
B plus normal T  cells. This response was delayed and did 
not reach the control response by the termination of the ex- 
periment (day 35).  This delayed response may be due to 
recovery of B cell function, or the donal expansion of a smaller 
number of responsive B cells. All mice receiving both T and 
B cells, with and without anti-8 treatment, made equivalent 
responses to chicken Ig. This indicates that B cell function 
has  not been generally affected by anti-&  For the rabbit 
Fab-specific B cells, the interaction with Fab anti-8 is a cross- 
linking interaction, since the membrane IgM and IgD on 
the antigen-specific B cells can recognize the rabbit Fab frag- 
ments bound to membrane IgD on the same cell or adjacent 
B cells. Therefore, the antigen-specific B cells could get a signal 
through their antigen receptors in the absence ofT cell help. 
Goodnow et al. (40) have shown using antibody transgenic 
mice that transfer  of mature antigen-specific  B  cells into 
antigen-bearing, T cell-tolerant mice results in B cell anergy. 
Also, B cell tolerance may require the involvement of slgM, 
which can occur only in the rabbit Fab-specific B cell popu- 
lation. Alternatively, it is possible that the transferred B cells, 
from anti-8-treated mice, retained some cell-associated or 
processed antigen, and induced tolerance in T cells after transfer 
into SCID recipients. 
Tolerance in the T  cell compartment has been shown to 
occur by at least three different mechanisms (3). Clonal dele- 
tion and anergy have both been shown to account for toler- 
ance in the thymus (41, 42) and in the periphery (43, 44). 
In addition, antigen-specific suppression by T cells has been 
described in peripheral tolerance to BSA (45) and to high 
doses of fowl gamma globulin (46).  Recently, it has been 
proposed that Thl and Th2 CD4 + T cell subsets may nega- 
tively regulate one another in vivo, accounting for earlier ob- 
servations that immune responses tend towards either delayed 
hypersensitivity or antibody formation (34). We are currently 
investigating the mechanism of the T cell defect with mixing 
experiments to look for active suppression. We are also looking 
for any set ofT cells from tolerant animals able to proliferate 
in response to antigen in vitro, since Whiteley et al. (47) found 
a proliferating population of T cells in tolerant animals that 
was unable to help antibody production, To date, we have 
been unable to demonstrate suppressor T cells in our mixing 
experiments, and find that in vitro proliferative responses of 
primed lymph node cells from anti-8-treated mice are reduced 
or absent.  Our IgG subclass profiles provide no evidence of 
activity of a different T  cell subset  in tolerant mice. 
The most straightforward mechanisms for the induction 
of tolerance by resting B cells would be anergy or deletion 
of naive antigen-specific T cells as a result of antigen presen- 
tation without appropriate costimulation. Resting B cells lack 
costimulatory activity (8, 48). Activation of B cells induces 
costimulatory activity (8, 49),  including the B7 molecule, 
which engages CD28 on the T cell (50, 51). This may ex- 
plain why F(ab')2 anti-8 is a less effective tolerogen (Fig. 3), 
and whole IgG anti-8 results in a polyclonal antibody response 
(29). 
It may be possible to induce tolerance to polypeptide drugs 
or antibodies used as therapeutic agents with this technique 
by coupling the drug to the Fab portion of an anti-8 mole- 
cule, or in the case of mAbs, by injecting a species-specific 
Fab anti-8 intravenously before the start of the therapy. 
As we have proposed (52), small B cells, acting as toledzing 
APCs, may maintain peripheral tolerance to their own Ig iso- 
types and idiotypes as well as to self-proteins not expressed 
or present at very low levels in the thymus. B cells capable 
of presenting low concentrations of self proteins must be au- 
toreactive.  Autoreactive B cells may persist in the periphery 
either as anergic cells at high self-antigen concentrations (40) 
136  Small B Cells as Antigen-presenting  Cells in Tolerance Induction or as functional cells at low self antigen concentrations (53). 
Both kinds of cells may play a role in maintenance of periph- 
eral T cell tolerance. When autoreactive B cells are activated 
by crossreacting foreign antigens and acquire costimulatory 
activity,  they  may  be  able  to  present  self-antigens  very 
efficiently to T  cells, and break stir-tolerance in the T  call 
compartment (54). 
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